The truth is out there: an overall perspective on androgen deprivation.
Androgen deprivation therapy (ADT) is a mainstay in the treatment of prostate cancer. The ideal timing, duration and composition of ADT remains undefined. At the present time, first-line therapy consists of orchiectomy, LHRH agonists, or combined androgen blockade (CAB). However, new combinations and treatment settings show promise for improving outcomes and decreasing toxicity.